New data confirm similar response rates with fewer toxicities when carboplatin is dropped from standard neoadjuvant therapy in early HER2-positive breast cancer.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/carboplatin-de-escalation-gains-ground-early-her2-breast-2026a10009g5?src=rss
Author :
Publish date : 2026-03-27 13:00:00
Copyright for syndicated content belongs to the linked Source.
